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HYPOTHESIS Open Access
Pharmacological conditioning for juvenile
idiopathic arthritis: a potential solution to
reduce methotrexate intolerance
Rosanne M. Smits1,2,3* , Dieuwke S. Veldhuijzen1,2,3, Henriet van Middendorp1,2, Petra C. E. Hissink Muller4,
Wineke Armbrust5, Elizabeth Legger5, Nico M. Wulffraat3 and Andrea W. M. Evers1,2,6
Abstract
Background: Methotrexate (MTX) therapy has proven to be a successful and safe treatment for Juvenile Idiopathic
Arthritis (JIA). Despite the high efficacy rates of MTX, treatment outcomes are often complicated by burdensome
gastro-intestinal side effects. Intolerance rates for MTX in children are high (approximately 50%) and thus far no
conclusive effective treatment strategies to control for side effects have been found. To address this need, this
article proposes an innovative research approach based on pharmacological conditioning, to reduce MTX
intolerance.
Presentation of the hypothesis: A collaboration between medical psychologists, pediatric rheumatologists,
pharmacologists and patient groups was set up to develop an innovative research design that may be
implemented to study potential improved control of side effects in JIA, by making use of the psychobiological
principles of pharmacological conditioning. In pharmacological conditioning designs, learned positive associations
from drug therapies (conditioning effects) are integrated in regular treatment regimens to maximize treatment
outcomes. Medication regimens with immunosuppressant drugs that made use of pharmacological conditioning
principles have been shown to lead to optimized therapeutic effects with reduced drug dosing, which might
ultimately cause a reduction in side effects.
Testing the hypothesis: This research design is tailored to serve the needs of the JIA patient group. We
developed a research design in collaboration with an interdisciplinary research group consisting of patient
representatives, pediatric rheumatologists, pharmacologists, and medical psychologists.
Implications of the hypothesis: Based on previous experimental and clinical findings of pharmacological
conditioning with immune responses, we propose that the JIA patient group is particularly suited to benefit from a
pharmacological conditioning design. Moreover, findings from this study may potentially also be promising for
other patient groups that endure long-lasting drug therapies.
Keywords: Juvenile idiopathic arthritis, Methotrexate intolerance, Side effects, Pharmacological conditioning,
Conditioned immune suppression
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Background
JIA is a childhood rheumatic disorder for which metho-
trexate (MTX) is the drug of choice, after the adminis-
tration of nonsteroidal anti-inflammatory drugs and
intra-articular corticosteroid injections, MTX is regarded
as a safe drug with a high efficacy rate up to 70% of the
patients reaching remission (1–5). However, MTX ther-
apy is hampered by side effects such as nausea and
vomiting, also known as MTX intolerance, which is one
of the leading causes of discontinuation or reduction of
MTX therapy and as a result causes a delay in reaching
remission (6, 7). Aside from pharmacological side effects
that occur after MTX intake, patients also report psy-
chological side effects prior to MTX intake and when
thinking of MTX, known as anticipatory and associative
complaints (8). These complaints, for example anticipa-
tory nausea, frequently occur and significantly contribute
to the burden the patient experiences (9). Since the de-
velopment of a clinical measure that determines the se-
verity of MTX intolerance, the Methotrexate Intolerance
Severity Scale (MISS), different cohort studies demon-
strated that approximately 50% of the patients suffer
from MTX intolerance (6–8, 10). Moreover, the MISS
brought forth new insights in the development of MTX
intolerance, indicating that the majority of patients de-
velop intolerance after 6 to 12months (7). To date, strat-
egies that focus on the reduction of MTX side effects,
consisting of anti-emetic therapy, changing the route of
administration, and dose reduction, have unfortunately
shown inconclusive results. However, these strategies
often focus on pharmacological side effects and overlook
the important psychological component in MTX intoler-
ance (8, 11–16). In order to optimally benefit from MTX
therapy, the urgent question arises how MTX intoler-
ance can be overcome for the psychological components,
including associative and anticipatory processes, of MTX
treatment. In this Hypothesis article, we propose a novel
approach that holds promise in reducing side effects and
potentially also in optimizing treatment effects, which is
known as pharmacological conditioning.
Presentation of the hypothesis
Behavioral learning theories, in particular classical con-
ditioning, explain how physiological responses arise from
learned associations, also known as conditioned re-
sponses. Classical conditioning was initially proposed by
Ivan Pavlov and states that physiological responses can
be triggered by a learned association between a stimulus
and a response. Pavlov showed that when a biologically
salient stimulus (the unconditioned stimulus, UCS for
example food) is repeatedly paired with an initial neutral
stimulus (the to-be conditioned stimulus, CS, for ex-
ample a bell), a conditioned response (CR, for example
the salivary response) can be triggered by the CS alone
after the association has been formed (see Fig. 1) (17).
Conditioned responses can manifest in both negative or
positive physiological responses. For example, anticipa-
tory nausea is an example of a conditioned response
Fig. 1 Schematic representation of conditioned immunosuppression
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associated with MTX-related nausea, which negatively
impacts health. However, positive physiological condi-
tioned responses can also be formed during frequent
and long-lasting drug therapies and simulate the initial
drug effect. Research has shown that the intake of a drug
can lead to a physiological response and that this learned
effect can be evoked by a placebo (an inert inactive
medication) (18–20). These conditioning principles have
been extensively studied in the experimental field with
various types of drug agents serving as the UCS (19, 21–
32), including immunological agents. More recently,
conditioning principles have been employed in RCTs to
relieve side effects or improve treatment efficacy (18,
20). It is therefore important to explore how learning
principles can be integrated in drug therapies, which will
be discussed further below (17, 31).
Pharmacological conditioning in experimental trials
Since the 1970’s, experimental conditioning trials have
been developed to investigate the potential to condition
pharmacological effects with immune responses. One of
the initial conditioning trials conducted in rats demon-
strated the ability to condition an immunological re-
sponse using the immunosuppressant cyclophosphamide
as a UCS, paired with saccharine (sugar water) as a CS
(21). The study findings showed that the administration
of saccharine at a later time resulted in a similar im-
munosuppressant response as cyclophosphamide, suc-
cessfully demonstrating the effects of a CR (21).
Subsequently, more conditioning trials followed with the
immunosuppressant drug cyclosporin A and the term
learned immune response was introduced (19, 23, 25–28,
31). In pharmacological conditioning trials, the magni-
tude of the CR is often measured on an immunological
level, for example by a significant reduction of interleu-
kin (IL)-2 and IFN-γ, mimicking the initial drug effects
of cyclosporin A (19, 23, 25, 26, 32). More recently, con-
ditioning effects have been found with different types of
drug agents, indicating that a CR can be learned through
different pathways and systems involved in the initial
drug effect (23, 26). For example, in pain studies CRs
were demonstrated with the opioid agonist morphine
hydrochloride or the nonopioid ketorolac tromethamine,
in allergy studies with the H1-receptor antagonist
desloratidine (21), and in neuroendocrine studies with
adrenaline, insulin, dexamethasone, glucose, IFN-β-1a or
sumatriptan (30).
Translating pharmacological conditioning to the clinical
context
In the last decade, experimental findings from condition-
ing trials have been translated to clinical trials in
humans and have shown promising results for different
patient groups (18, 33–36). These studies utilized
pharmacological conditioning for different objectives.
One important objective has been to add identical look-
ing placebos as CS, to evoke CRs in order to maximize
therapeutic outcomes. Recently, a clinical study demon-
strated that adding placebos as ‘dose extenders’ success-
fully enhanced therapeutic effects of cyclosporin A in
renal transplant patients (34). Another important object-
ive of pharmacological conditioning has been to control
for side effects. This approach may be particularly rele-
vant for the JIA patient group, because of the possibility
of dose reduction while maintaining treatment efficacy.
A double blind placebo-controlled RCT with patients
suffering from psoriasis demonstrated similar thera-
peutic effects of corticosteroids combined with condi-
tioning principles to treat cutaneous lesions with a 25%
dose reduction (18). This study used a variable
reinforcement schedule in which full doses of medica-
tion were intermittently replaced by lower doses com-
bined with placebos to evoke a CR. Furthermore, these
effects were not found in the dose control group that
was administered the same dose. In dose control groups,
the same cumulative amount of drug dosing as the con-
ditioning group is administered but without the use of
variable reinforcement principles (18). Effects of
pharmacological conditioning have been demonstrated
in children as well. In a study where children with
ADHD received 50–75% reduced dosing of mixed am-
phetamine salts, a significant reduction in side effects
was reported compared to the 100% dosing group, while
maintaining similar therapeutic results (see Appendix 1
for an example of a medication schedule using variable
reinforcement) (35). These findings hold great potential
for the integration of pharmacological conditioning prin-
ciples in various populations and for various drug effects,
including younger populations.
Testing the hypothesis
Considering the extensive field of pharmacological con-
ditioning in experimental animal and human trials, and
the possibility that different patient groups may benefit
from these applications, we believe the time is now to
capitalize on this treatment method. We therefore devel-
oped a novel design based on pharmacological condi-
tioning for JIA patients, which can be found in Fig. 2.
This study design is based on the assumption that condi-
tioning effects are formed during a baseline acquisition
period and are evoked in the intervention period by
making use of placebo-controlled dose reduction. Partic-
ipants from age 4 to 17 (at the time of JIA diagnosis)
with all JIA subtypes (with the exception of systemic
JIA) could be included. During the baseline period,
stable doses of oral MTX should be administered (12,5–
15mg/m2/week) allowing the formation of a positive as-
sociation between the drug and its positive therapeutic
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effects. The study should only use oral MTX, because it
is important that the conditioned stimulus is the same
for all participants to allow a comparison between
groups. The baseline period ends after remission is
achieved (based on a JADAS score of ≤3 or on the as-
sessment of the pediatric rheumatologist) with a max-
imum duration of 6 months (7). After the baseline
period, patients can be randomized to the intervention
or control group where allocation should be stratified by
weight (e.g., below or above 30 kg) to ensure for numer-
ical equality. During the intervention period, conditioned
responses can then be utilized by integrating pharmaco-
logical conditioning principles through a variable
reinforcement schedule in which intermittent standard
MTX doses and lower MTX doses supplemented with
placebos are provided to evoke a CR in the low dose
weeks (see Appendix 1 for an example of a medication
schedule). Similar to previous conditioning trials, we
propose that this reduced drug dosing may ultimately
lead to lower MTX intolerance, while maintaining thera-
peutic efficacy (18, 35). During the development of this
design, different stakeholders involved in JIA treat-
ment were consulted to discuss a possible design for
pharmacological conditioning (i.e. pediatric rheuma-
tologists, pharmacologists, medical psychologists and
patient groups). Overall, and specifically expressed by
patients, the main priority was to reduce MTX in-
tolerance. For this reason, the primary aim should
preferably focus on MTX intolerance with MISS as
the primary outcome. This study would therefore be
powered to find a difference in MISS scores between
the experimental and the control group after the
intervention period (with lower MISS scores in the
experimental compared to the control group). For a
secondary analysis, focus can be on the effects of con-
ditioning on an immunological level, for example in
clinical measures (e.g. erythrocyte sedimentation rate
and C-reactive protein level), cytokines (IL-1β, IL-6,
IL-8, Interferon-γ (IFN-γ), and Tumour Necrosis
Factor-α (TNF-α), MRP8/14 serum (to compare flare
risks for both groups) and polyglutamates in erythro-
cytes (to compare intracellular buildup of MTX in
both groups, which may be mimicked by the condi-
tioned response in de intervention group). Several fac-
tors were taken into account while conceptualizing
the current design. One important consideration was
Fig. 2 An overview of the hypothesized trial design. The clinical study design closely follows current pharmacological treatment
recommendations. Baseline period: Patients diagnosed with JIA and eligible for stable standard pharmacological treatment (12,5 mg/m2–15 mg/
m2) will start with MTX. Intervention period: Patients who complete the baseline period without protocol violations continue to the second phase
of the study and will be randomized double-blind to one of the following groups: control group (standardized stable treatment dosages of MTX
as a continuation of the baseline period for 9 months) or pharmacological conditioning group (variable doses of MTX interspersed with placebos
for 9 months). Primary outcome (MISS) will be measured at 15months (T5). This study will be closed with an end-of-study one year after the
intervention period (T6). Flare-ups and side effects will be monitored during clinical visitations.
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a dose control group. For methodological purposes,
pharmacological conditioning designs often integrate a
dose control group to expose direct effects of condition-
ing. In clinical studies with vulnerable patient groups, like
children with JIA, a dose control group would be un-
wanted as this may cause for higher flare-up risks. How-
ever, cytokine levels and other markers for the level
inflammation make it possible to investigate the effects of
conditioning on an immunological level. Another consid-
eration could be to first implement a conditioning design
in an adult population, for example in patients with
rheumatoid arthritis. However, in contrast to the JIA
population, side effects in the adult population are less
common and therefore this population may be suboptimal
to test this design first (37). Nonetheless, a currently on-
going pharmacological conditioning study with MTX and
RA patients did indicate the potential for conditioning
with MTX (38). Finally, an important consideration is
whether conditioning of therapeutic effects may also lead
to conditioning of the unwanted side effects. Because con-
ditioning plays a large role in the proposed design, this
may also pose as a concern. However, recommendations
that focused specifically on the psychological constructs of
side effects (nocebo effects) stress the importance of man-
aging patient expectations, considering patient–physician
communication and relationships, positive framing of
treatment information and emphasizing therapeutic ef-
fects, which can be employed by focusing on the positive
conditioning effects in this study design (39, 40). To opti-
mally integrate conditioning principles in drug regimens,
it would therefore be important to explain the potential of
pharmacological conditioning by primarily focusing on
the therapeutic effects of MTX (40). Moreover, previous
trials that made use of pharmacological conditioning
showed a clinically meaningful reduction of side effects
(35, 41, 42). Nevertheless, it is of utmost importance to
closely monitor side effects during the whole duration of
treatment.
Implications of the hypothesis
To conclude, converging evidence has demonstrated the
potential to condition immune responses and the possi-
bility to integrate this in treatment designs. Pharmaco-
logical conditioning principles show potential to address
an important problem in JIA treatment: it can be used
to optimize MTX therapy by dose reduction and there-
fore possibly lower side effects while maintaining thera-
peutic efficacy. Based on the difficulties that the JIA
patient group faces, this group may particularly benefit
from this proposed study design. Ultimately, implement-
ing a pharmacological conditioning design would not
only have implications for the JIA patient group, but
may also show potential for other patient groups that
endure long-lasting drug therapies.
Appendix
Appendix 1: An example MTX schedule for the inter-
vention (conditioning) group and control group. The
medication schedules that were developed by our group
start from 7,5 mg up to 20mg. Depending on body sur-
face area we made schedules according to the ratio of
placebos and the dose of MTX. For example, a child that
receives 15 mg will receive 2 MTX pills (5 mg) during
the low dose week interspersed with placebos (3:1 ratio).
During baseline period (week 1 t/m 26) patients receive
the same amount as the control group
Week Conditioning group Control group
27 15 mg MTX/wk 15 mg MTX/wk
28 15 mg MTX/wk 15 mg MTX/wk
29 5 mg MTX/wk 15 mg MTX/wk
30 15 mg MTX/wk 15 mg MTX/wk
31 15 mg MTX/wk 15 mg MTX/wk
32 5 mg MTX/wk 15 mg MTX/wk
33 15 mg MTX/wk 15 mg MTX/wk
34 5 mg MTX/wk 15 mg MTX/wk
35 15 mg MTX/wk 15 mg MTX/wk
36 5 mg MTX/wk 15 mg MTX/wk
37 5 mg MTX/wk 15 mg MTX/wk
38 15 mg MTX/wk 15 mg MTX/wk
39 5 mg MTX/wk 15 mg MTX/wk
40 5 mg MTX/wk 15 mg MTX/wk
41 15 mg MTX/wk 15 mg MTX/wk
42 5 mg MTX/wk 15 mg MTX/wk
43 5 mg MTX/wk 15 mg MTX/wk
44 15 mg MTX/wk 15 mg MTX/wk
45 5 mg MTX/wk 15 mg MTX/wk
46 5 mg MTX/wk 15 mg MTX/wk
47 15 mg MTX/wk 15 mg MTX/wk
48 5 mg MTX/wk 15 mg MTX/wk
49 5 mg MTX/wk 15 mg MTX/wk
50 5 mg MTX/wk 15 mg MTX/wk
51 15 mg MTX/wk 15 mg MTX/wk
52 5 mg MTX/wk 15 mg MTX/wk
53 5 mg MTX/wk 15 mg MTX/wk
54 5 mg MTX/wk 15 mg MTX/wk
55 15 mg MTX/wk 15 mg MTX/wk
56 5 mg MTX/wk 15 mg MTX/wk
57 5 mg MTX/wk 15 mg MTX/wk
58 5 mg MTX/wk 15 mg MTX/wk
59 15 mg MTX/wk 15 mg MTX/wk
60 5 mg MTX/wk 15 mg MTX/wk
61 5 mg MTX/wk 15 mg MTX/wk
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Appendix (Continued)
Week Conditioning group Control group
62 15 mg MTX/wk 15 mg MTX/wk
63 5 mg MTX/wk 15 mg MTX/wk
64 5 mg MTX/wk 15 mg MTX/wk
65 5 mg MTX/wk 15 mg MTX/wk
Cumulative dose(%) 335mg (57%) 585mg (100%)
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